

# 2023 Alzheimer's Disease Public Educational Forum

Chairs: Ranjan Duara, MD, FAAN, Mount Sinai Medical Center, Miami Beach  
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine

Sunday, April 2, 2023

1:30 pm - 4:20 pm US Eastern Time

The FDA has provided accelerated approvals for the first time for two disease-modifying drugs for Alzheimer's disease. These two drugs, and one additional drug which is expected to receive accelerated approval in 2023, are monoclonal antibody treatments, designed to remove the toxic beta amyloid protein, associated with Alzheimer's disease, from the brain.

In this Public Information Forum our goal is to provide information and answer questions about this new class of drugs for Alzheimer's disease, from six experts in the field.

The topics which will be addressed include:

- clarification about how the treatment works and modifies the course of Alzheimer's disease and its symptoms,
- the clinical meaningfulness of the reported extent of slowing of progression of the disease,
- the side effect profile of the approved drug,
- the expected duration of treatment and how to determine when to stop treatment,
- the contraindications for treatment with these drugs,
- the alternatives to treatment with this new generation of drugs, and
- the balance between efficacy, side effects, cost of treatment and guidance (for a particular patient) about how to proceed.

FREE REGISTRATION

Program details and online  
registration at  
[mcisymposium.org/forum](https://mcisymposium.org/forum)

